The treatment of fibrinogen deficiency-related bleeding disorders and acquired hypofibrinogenemia remains heavily reliant on blood-derived products such as fibrinogen concentrate, a mainstay therapy constrained by limited supply, viral contamination risks,...
Wang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: